Stockscreener 앱 받기
0.50
2.19%
-0.0112
시간 외 거래:
.49
-0.01
-2.00%
전일 마감가:
$0.5112
열려 있는:
$0.5202
하루 거래량:
498.83K
Relative Volume:
0.37
시가총액:
$6.95M
수익:
$19.57M
순이익/손실:
$-25.12M
주가수익비율:
-0.2163
EPS:
-2.3114
순현금흐름:
$-19.71M
1주 성능:
-18.53%
1개월 성능:
-16.53%
6개월 성능:
-74.75%
1년 성능:
-79.84%
1일 변동 폭
$0.45
$0.5202
1주일 범위
$0.45
$0.6157
52주 변동 폭
$0.45
$7.95
비보스 테라퓨틱스 Stock (VVOS) Company Profile
명칭
Vivos Therapeutics Inc
전화
(866)908-4867
주소
7921 SOUTHPARK PLAZA,, LITTLETON
Compare VVOS vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VVOS
Vivos Therapeutics Inc
|
0.50 | 6.95M | 19.57M | -25.12M | -19.71M | -2.3114 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
비보스 테라퓨틱스 주식(VVOS)의 최신 뉴스
Vivos Therapeutics Inc (VVOS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Vivos Therapeutics Inc (VVOS) Institutional Confidence - TradingKey
Vivos Therapeutics Inc (VVOS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vivos Therapeutics Inc (VVOS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vivos Therapeutics Inc (VVOS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Vivos Therapeutics Inc (VVOS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vivos Therapeutics Inc (VVOS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Vivos Therapeutics Inc (VVOS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vivos Therapeutics Inc (VVOS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Vivos Therapeutics (NASDAQ: VVOS) outlines proposed tradable rights offering terms - Stock Titan
Vivos Therapeutics Partners with Florida Cardiology Group to Expand Sleep Apnea and Insomnia Treatment for Cardiovascular Patients – Minichart - Minichart
Vivos Therapeutics Forms AIM Florida Sleep Care Venture - TipRanks
Vivos Therapeutics (NASDAQ: VVOS) inks AIM Florida deal with major cardiology group - Stock Titan
Vivos Therapeutics Inc. (VVOS) Q1 2026 Earnings: EPS Misses Estimates as Stock DeclinesLong-Term Guidance - lwvtexas.org
Vivos Therapeutics Plans to File for Proposed Rights Offering - Moomoo
Vivos Therapeutics plans rights offering for shareholders By Investing.com - Investing.com South Africa
Vivos Therapeutics plans rights offering for shareholders - Investing.com
Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering - The Manila Times
Vivos plans 9‑month tradable rights for shareholders to buy stock - Stock Titan
Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients - The Manila Times
Vivos Therapeutics Enters Collaboration With Florida Firm to Treat Cardiovascular Patients - Moomoo
VVOS: Capital-light, scalable sleep apnea treatment model targets rapid, profitable national expansion - TradingView
VVOS: Rapidly scaling sleep apnea treatment with high margins and unique FDA-cleared devices - TradingView
Vivos Therapeutics, Inc. to Present at The Small Cap Showcase & WTR Insights on June 9, 2026 - Quiver Quantitative
Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026 - The Manila Times
Vivos Therapeutics Announces $4.5 Million Debt-to-Equity Exchange Agreement to Support Nasdaq Listing and Strengthen Financial Position – Minichart - Minichart
Vivos Therapeutics Restructures Debt to Support Nasdaq Compliance - TipRanks
Vivos Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
[8-K] Vivos Therapeutics, Inc. Reports Material Event - Stock Titan
Vivos Therapeutics agrees to debt-to-equity exchange with lender By Investing.com - Investing.com South Africa
6/5/2026 Market UpdateWinners: NOTV, STI, BGMSLosers: BIGGQ, NUWE, CYPHS&P 500: -2.6% - Trefis
Vivos Therapeutics Shares Surge After $4.5 Million Debt Conversion Fuels Nasdaq Optimism - TechStock²
Vivos Therapeutics (VVOS) Stock: Debt Exchange Plan Fuels Investor Optimism - parameter.io
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Vivos Therapeutics agrees to debt-to-equity exchange with lender - Investing.com
Vivos Therapeutics Announces Debt Exchange Agreement with Streeterville Capital to Strengthen Financial Position - Quiver Quantitative
Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing - marketscreener.com
Press Release: Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million From Streeterville Capital to Support Continued Nasdaq Listing - Moomoo
Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel® Precision Radionuclide Therapy™ - Yahoo Finance
CrowdStrike To Surge Nearly 25%? Here Are 10 Notable Analyst Calls From Thursday - Benzinga
Vivos Therapeutics (VVOS) Gains 4.5% as Stock Tests Key Resistance at $0.73Growth Stock Picks - The Legal Advocate
VVOS Should I Buy - Intellectia AI
Vivos Therapeutics Inc (VVOS) Q1 2026 Earnings Call Highlights: Revenue Surges Amid Strategic Shifts By GuruFocus - Investing.com Canada
VVOS - Finviz
Vivos Therapeutics Balances Rapid Growth With Cash Strain - The Globe and Mail
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q1 2026 Earnings Call Transcript - Insider Monkey
Vivos Therapeutics Earnings Call: Growth Meets Cash Strain - The Globe and Mail
Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update - The Manila Times
Vivos Therapeutics, Inc. 1Q 2026: Revenue $5.14M, EPS $(0.52) — 10-Q Summary - TradingView
Vivos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Vivos Therapeutics (NASDAQ: VVOS) Q1 2026 loss and going concern risk - Stock Titan
비보스 테라퓨틱스 (VVOS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
자본화:
|
볼륨(24시간):